Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
30.84
-0.09 (-0.29%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Avidity Biosciences Revenue
In the year 2024, Avidity Biosciences had annual revenue of $10.90M with 13.99% growth. Avidity Biosciences had revenue of $2.97M in the quarter ending December 31, 2024, with 35.57% growth.
Revenue (ttm)
$10.90M
Revenue Growth
+13.99%
P/S Ratio
340.22
Revenue / Employee
$27,870
Employees
391
Market Cap
3.71B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
RNA News
- 6 days ago - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 19 days ago - Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 26 days ago - Avidity Biosciences to Participate in Upcoming Investor Conference - PRNewsWire
- 27 days ago - Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - PRNewsWire
- 6 weeks ago - Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial - PRNewsWire
- 6 weeks ago - Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 2 months ago - Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases - PRNewsWire
- 2 months ago - Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - PRNewsWire